Literature DB >> 26231082

Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.

José Wanderlan Pontes Espíndola1, Marcos Veríssimo de Oliveira Cardoso1, Gevanio Bezerra de Oliveira Filho1, Dayane Albuquerque Oliveira E Silva1, Diogo Rodrigo Magalhaes Moreira2, Tanira Matutino Bastos2, Carlos Alberto de Simone3, Milena Botelho Pereira Soares4, Filipe Silva Villela5, Rafaela Salgado Ferreira5, Maria Carolina Accioly Brelaz de Castro6, Valéria Rego Alves Pereira6, Silvane Maria Fonseca Murta7, Policarpo Ademar Sales Junior7, Alvaro José Romanha7, Ana Cristina Lima Leite8.   

Abstract

The discovery of new antiparasitic compounds against Trypanosoma cruzi, the etiological agent of Chagas disease, is necessary. Novel aryloxy/aryl thiosemicarbazone-based conformationally constrained analogs of thiosemicarbazones (1) and (2) were developed as potential inhibitors of the T. cruzi protease cruzain, using a rigidification strategy of the iminic bond of (1) and (2). A structure-activity relationship analysis was performed in substituents attached in both aryl and aryloxy rings. This study indicated that apolar substituents or halogen atom substitution at the aryl position improved cruzain inhibition and antiparasitic activity in comparison to unsubstituted thiosemicarbazone. Two of these compounds displayed potent inhibitory antiparasitic activity by inhibiting cruzain and consequently were able to reduce the parasite burden in infected cells and cause parasite cell death through necrosis. In conclusion, we demonstrated that conformational restriction is a valuable strategy in the development of antiparasitic thiosemicarbazones.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Chagas disease; Conformationally constrained analogs; Cruzain; Necrosis; Thiosemicarbazone; Trypanosoma cruzi

Mesh:

Substances:

Year:  2015        PMID: 26231082     DOI: 10.1016/j.ejmech.2015.06.048

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  5 in total

1.  Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei.

Authors:  Glaécia An Pereira; Lucianna H Santos; Steven C Wang; Luan C Martins; Filipe S Villela; Weiting Liao; Marco A Dessoy; Luiz C Dias; Adriano D Andricopulo; Mariana Af Costa; Ronaldo Ap Nagem; Conor R Caffrey; Klaus R Liedl; Ernesto R Caffarena; Rafaela S Ferreira
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

2.  Bis(4-meth-oxy-chalcone 4-ethyl-thio-semi-carbazon-ato-κ2N1,S)zinc(II): crystal structure and Hirshfeld surface analysis.

Authors:  Ming Yueh Tan; Karen A Crouse; Thahira B S A Ravoof; Mukesh M Jotani; Edward R T Tiekink
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2018-01-12

3.  One-Pot Synthesis of Novel Thiazoles as Potential Anti-Cancer Agents.

Authors:  Abdelwahed R Sayed; Sobhi M Gomha; Eman A Taher; Zeinab A Muhammad; Hesham R El-Seedi; Hatem M Gaber; Mahgoub M Ahmed
Journal:  Drug Des Devel Ther       Date:  2020-04-03       Impact factor: 4.162

4.  Thio- and selenosemicarbazones as antiprotozoal agents against Trypanosoma cruzi and Trichomonas vaginalis.

Authors:  Alexandra Ibáñez-Escribano; Cristina Fonseca-Berzal; Mónica Martínez-Montiel; Manuel Álvarez-Márquez; María Gómez-Núñez; Manuel Lacueva-Arnedo; Teresa Espinosa-Buitrago; Tania Martín-Pérez; José Antonio Escario; Penélope Merino-Montiel; Sara Montiel-Smith; Alicia Gómez-Barrio; Óscar López; José G Fernández-Bolaños
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

5.  Multiparameter Optimization of Trypanocidal Cruzain Inhibitors With In Vivo Activity and Favorable Pharmacokinetics.

Authors:  Ivani Pauli; Celso de O Rezende; Brian W Slafer; Marco A Dessoy; Mariana L de Souza; Leonardo L G Ferreira; Abraham L M Adjanohun; Rafaela S Ferreira; Luma G Magalhães; Renata Krogh; Simone Michelan-Duarte; Ricardo Vaz Del Pintor; Fernando B R da Silva; Fabio C Cruz; Luiz C Dias; Adriano D Andricopulo
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.